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Objectives. Examine associations of favorable levels of all cardiovascular disease (CVD) risk factors (RFs)
[i.e., low risk (LR)] at younger ages with high sensitivity C-reactive protein (hs-CRP) at older ages.
Methods. There were 1324 participants ages 65–84 years with hs-CRP ≤ 10 mg/L from the Chicago Healthy
Aging Study (2007–2010), and CVD RFs assessed at baseline (1967–73) and 39 years later. LRwas deﬁned as un-
treated blood pressure (BP) ≤120/≤80 mmHg, untreated serum total cholesterol b200 mg/dL, body mass index
(BMI) b25 kg/m2, not smoking, and nodiabetes. Hs-CRPwasnatural log-transformedor dichotomized as elevated
(≥3 mg/L or ≥2 mg/L) vs. otherwise.Results. With multivariable adjustment, the odds ratios (95% conﬁdence intervals) for follow-up hs-CRP
≥3 mg/in participants with baseline 0 RF, 1 RF and 2+ RFs compared to those with baseline LR were 1.35
(0.89–2.03), 1.61 (1.08–2.40) and 1.69 (1.04–2.75), respectively. There was also a graded, direct association
across four categories of RF groups with follow-up hs-CRP levels (β coefﬁcient/P-trend = 0.18/0.014). Associa-
tionsweremainly due to baseline smoking and BMI, independent of 39-year change in BMI levels. Similar trends
were observed in gender-speciﬁc analyses.
Conclusions. Favorable levels of all CVDRFs in younger age are associatedwith lower hs-CRP level in older age.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
High-sensitivity C-reactive protein (hs-CRP), an acute phase reactant
and a marker for systemic inﬂammation, has been found to be associat-
ed with future cardiovascular disease (CVD) events and mortality
(Buckley et al., 2009; Kengne et al., 2012; Libby et al., 2002; Ridker,
2003; Ridker et al., 2000; Strandberg and Tilvis, 2000) as well as with
single CVD risk factors (RFs), including obesity or body mass index
(BMI) (Arena et al., 2006; Ganguli et al., 2011; Ishii et al., 2012; Khoo
et al., 2011; Strandberg and Tilvis, 2000; Visser et al., 1999), smoking
(Khoo et al., 2011; Strandberg and Tilvis, 2000), blood pressure (Khoo
et al., 2011; Lakoski et al., 2005), serum cholesterol (Chiu et al., 2012;ctor; hs-CRP, high sensitivity C-
HA, Chicago Heart Association
Study; SBP, systolic bloodpres-
hic;HRT, hormone replacement
e Medicine, Feinberg School of
e Drive, Suite 1400, Chicago, IL
u).
. This is an open access article underGanguli et al., 2011), and diabetes (Chiu et al., 2012). However, no
data are available on the associations between having a favorable level
of all CVD RFs (i.e., low risk — LR) at younger ages and hs-CRP levels at
older ages.
Many studies have indicated that the beneﬁts of having LRproﬁle in-
clude increased longevity (Lloyd-Jones et al., 2006; Stamler et al., 1999),
lower morbidity (Lloyd-Jones et al., 2006), better health-related quality
of life (Daviglus et al., 2003; Strandberg et al., 2004), and lower heath
care costs (Daviglus et al., 2005). Hence, the critical importance of LR
concept in overcoming the CVD epidemic has been increasingly recog-
nized (Lloyd-Jones et al., 2010). Establishing the long-term association
of LRproﬁle earlier in life andhs-CRP levels later in lifewill addmore ev-
idence on the beneﬁts of LR on subsequent health status and, therefore
support efforts to increase the prevalence of LR, in keeping with strate-
gic goals of the American Heart Association for cardiovascular health
promotion and disease prevention through 2020 and beyond (Lloyd-
Jones et al., 2010).
We examined these associations using data on 962 men and 362
women from the Chicago Healthy Aging Study (CHAS). Participants'
risk proﬁles were ascertained in both young adulthood/early middle
age (1967–73) and 39 years later (2007–10). Hs-CRP was assessed atthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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younger/middle ages is associated with lower levels of inﬂammatory
markers of CHD/CVD assessed later in life, and that a graded direct asso-
ciation exists across baseline RF groups – LR to very high risk – with
levels of inﬂammatorymarkers at follow-up. The long-term associations
of individual CVD risk factors and hs-CRP levels at older ages were also
examined. In addition, the question of whether the 39-year change in
BMI would modify the above associations was investigated.Methods
The Chicago Healthy Aging Study (CHAS)
CHAS is a study of a subset of participants from the Chicago Heart
Association Detection Project in Industry (CHA), a prospective co-
hort study of 39,665 men and women ages 18–74 in work places
throughout the Chicago area in 1967–73, focused on RFs for cardio-
vascular diseases. Details of the CHA (Stamler et al., 1993; Stamler
et al., 1975) and CHAS (Pirzada et al., 2013; Vu et al., 2012) studies
have been published. Brieﬂy, there were 11,908 potential CHAS
participants based on criteria as follows: CHA survivors, aged 65–
84 years during 2007–10, free of major ECG abnormalities or myo-
cardial infarction (MI) at the CHA examination (baseline). We used
stratiﬁed sampling method to recruit CHAS participants based on
their baseline RF proﬁle (LR and not LR). Fifty-nine percent (n =
7090) of names (988 LR and 6102 not LR) were randomly selected
for contacting by mail or phone. We successfully contacted 2799 per-
sons during 2007–10, but 1404 persons refused to participate in
CHAS,which provided a participation rate of 49.8%. The ﬁnal CHAS sam-
ple included 1395 participants (28% women, 9.3% African American,
19.5% baseline LR). LR participants were oversampled to obtain ade-
quate numbers for between-group comparisons (Vu et al., 2012).
In general, comparing CHAS participants and non-participants by
baseline LR and non-LR status of 11,908 potential CHAS-eligible CHA
participants (aged 65–84 years in 2007–2010 and presumed to be
alive based on the last received vital status information from National
Death Index and CMS records), those who participated in CHAS were
slightly younger, less likely to be Black and male, more educated and
slightly healthier with regard to CVD RFs than non-CHAS participants,
especially for the non-LR group (results not tabulated).
Data on CVD risk proﬁles, including systolic/diastolic blood pressure
(SBP/DBP), serum total cholesterol, BMI, diabetes, smoking history,
medical diagnoses and treatment, ECGs, and demographic characteris-
tics, were collected at both baseline and follow-up. Data on subclinical
measures and inﬂammatory markers were collected at follow-up
(Fig. 1).
All examination procedures were performed by trained and certi-
ﬁed staff. The study was approved by the Northwestern UniversityFig. 1. Chicago HealtInstitutional Review Board; signed informed consent was obtained
from all participants.
Exclusions
Of 1395 CHAS participants examined at the clinic, 71 were hierar-
chically excluded for the following reasons: missing data on hs-CRP
(n = 3), hs-CRP N10 mg/L (n = 67) due to suggestions that these
values may present acute inﬂammation (Ridker, 2003), and missing
covariates at the follow-up examination (n= 1). Thus, the ﬁnal sam-
ple included 1324 CHAS participants. Additionally, because some ev-
idence suggests that CRP elevations above 10 mg/L may present only
in very obese persons rather than in those with acute inﬂammation
(Ishii et al., 2012), those with hs-CRP N10 mg/L were included in a
sensitivity analysis, with the sample of 1391 participants.
Follow-up hs-CRP measurement
Hs-CRP at follow-upwasmeasured in serum samples by the Univer-
sity of Minnesota Physicians Outreach Laboratories using a latex-
particle enhanced immunoturbidimetric assay kit and read on the
Roche Modular P Chemistry analyzer (Roche Diagnostics, Indianapolis,
IN 46250). Hs-CRP was expressed in milligrams per liter (mg/L) and
was dichotomized as ≥3 mg/L (cut point indicating elevated risk for
CVD) (Wong and Malik, 2005) or elevated CRP vs. otherwise
(b3 mg/L). Another cut-point of hs-CRP ≥2 mg/L was also used for
a sensitivity analysis (Goff et al., 2014).
Deﬁnition of baseline risk factor status
Baseline RF status was categorized into 4 groups: 1) Low risk: all
RFs at favorable levels — SBP/DBP ≤120/≤80 mm Hg and not taking
antihypertensive medication; serum total cholesterol b200 mg/dL
and not taking lipid-lowering medication; BMI b25 kg/m2; not
smoking; and no diabetes. Not LR participants then were further
classiﬁed as: 2) 0 RF (but with one or more not favorable levels
[i.e., SBP 121–139 mm Hg or DBP 81–89 mm Hg and not taking anti-
hypertensive medication; serum cholesterol 200−239 mg/dL and
not taking lipid-lowering medication; BMI 25.0–29.9 kg/m2]); or
3) 1 adverse RF only (1 RF); or 4) 2 or more adverse RFs (2+ RFs)
[i.e., SBP N140 or DBP N90 mm Hg or taking antihypertensive medi-
cation; serum cholesterol N240 mg/dL or taking lipid-lowering med-
ication; BMI N30 kg/m2; current smoking; or diabetes].
Data analyses
Descriptive characteristics were compared across the 4 baseline risk
categories using the F tests (for continuous variables) or Chi-square
tests (for binary variables). Age-sex-race adjusted prevalence of hs-hy Aging Study.
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using general linear models.
For multivariate analyses, logistic regression was used to examine
the relationship of baseline CVD risk status (with LR as the reference
group) to hs-CRP ≥3 mg/L at follow-up. Analyses were adjusted for
baseline age, race, and sex (Model 1), and then were further adjusted
for educational attainment and covariates with potential impact on
CRP levels, e.g., presence of major ECG abnormalities or CVD, cancer,
and use of aspirin and lipid-lowering medication at follow-up (Model
2). Logistic regression models were also used with baseline RF status
as a continuous variable to test for trends across RF strata — from LR
to 2+ RFs. Analyses were repeated with the cut-point of hs-CRP
≥2mg/L. In addition, multiple linear regression analysis was performed
to test for the linear association of baseline RF strata and follow-up hs-
CRP. Because the distribution of follow-up hs-CRP levels was skewed,
follow-up hs-CRP was natural log-transformed in this analysis.
There were 17 participants who reported having fever in the two
weeks prior to follow-up examination, and 30 women who reported
using hormone replacement therapy (HRT) at follow-up. Because
those conditions may alter the hs-CRP level (Skouby et al., 2002), we
performed sensitivity analyses with those participants excluded from
the analysis. In addition,we also performed sensitivity analyseswithout
the exclusion of 67 participants with hs-CRP N 10 mg/L in the sample.Table 1
Selected baseline (1967–73) and follow-up (2007–10) characteristics, all participants and by b
Characteristics [mean (SD) or no. (%)e] Baseline risk factor status
All LRa
No. of people 1324 259
Baseline
Age, mean (SD), years 32.8 (4.6) 32.1 (5.0
Female, no. (%) 362 (27.3) 130 (50.
Race, no. (%)
Black 118 (8.9) 19 (7.3)
Non-Hispanic White 1172 (88.5) 230 (88.
Hispanic or Asian 34 (2.6) 10 (3.9)
Education, mean (SD), y 14.8 (2.3) 14.8 (2.4
Smoking status, no. (%)
Never smoker 608 (45.9) 168 (64.
Former smoker 397 (30.0) 91 (35.1
Current smoker 319 (24.1) 0 (0.0)
BMI, mean (SD), kg/m2 24.9 (3.4) 22.1 (2.0
BMI ≥30.0 kg/m2, no. (%) 83 (6.3) 0 (0.0)
SBP, mean (SD), mm Hg 127.1 (15.1) 113.8 (6
DBP, mean (SD), mm Hg 75.5 (9.8) 68.9 (7.3
Hypertensionc, no. (%) 373 (28.2) 0 (0.0)
Serum cholesterol, mean (SD), mg/dL 187.4 (35.2) 166.1 (2
Hypercholesterolemiac, no. (%) 93 (7.0) 0 (0.0)
Diabetes mellitus, no. (%) 9 (0.7) 0 (0.0)
Follow-up (FU)
Follow-up RF status, no. (%)
LR 25 (1. 9) 14 (5.4)
0 RF 154 (4.6) 42 (16.2
1 only RF 341 (25.8) 85 (32.8
≥2 RFs 804 (60.7) 118 (45.
Current CVD or major ECG abnormalities, no. (%) 437 (33.0) 61 (23.6
Current cancer, no. (%) 369 (27.9) 77 (29.7
Current taking statin, no. (%) 801 (60.5) 122 (47.
Current taking aspirin, no. (%) 694 (52.4) 108 (41.
Hs-CRP ≥ 3 mg/L, no. (%) 286 (21.6) 51 (19.7
Hs-CRP ≥ 2 mg/L, no. (%) 443 (33.5) 80 (30.9
Hs-CRP, mean (SD), mg/L 2.1 (2.0) 2.0 (1.9)
Abbreviations: BMI, bodymass index; hs-CRP, high sensitivity C-reactive protein; CVD, cardiov
risk factor; SBP, systolic blood pressure; SD, standard deviation.
Deﬁnition of baseline RF status:
–Not applicable, as the variable is counted in the RF status algorithm.
a Favorable level of all major CVD RFs (BP ≤120/≤80mmHg and no antihypertensivemedica
25 kg/m2, no diabetes).
b Unfavorable/borderline SBP/DBP or serum total cholesterol, not smoking, BMI 25.0-29.9 kg
c High SBP/DBP (≥140/90) or using antihypertensive medication, serum total cholesterol ≥ 2
d P values for overall group comparisons based on χ2 or F-test except for baseline RF compo
e Column percentages were computed.Models with individual RFs were used to examine the association of
each RF separately with CRP. Further, models including 39-year change
in BMI were used to explore whether change in BMI level played a role
in the association of baseline BMI and CRP levels. Finally, secondary
analyses stratiﬁed by sex were performed to assess possible effects of
sex on the association. All analyses used SAS statistical software version
9.3 (SAS Institute Inc, Cary, NC).Results
Of the 1324 CHAS participants with hs-CRP b10 mg/L at follow-up
(27.3% women, 8.9% African American), baseline mean age was 32.8
(SD, 4.6) years and the follow-up mean age was 71.3 (SD, 4.6) years.
At baseline, 19.6% of participants (n = 259) were LR and 14.5% (n =
193) had 2 or more RFs. Participants who were LR at baseline tended
to be female, non-Black, and better educated than other participants.
They also tended to have higher rates of being LR at follow-up compared
with other baseline RF groups (5.4% vs. 0.5–1.7%), and have lower prev-
alence of follow-up CVD/major ECG abnormalities, or use of aspirin or
lipid-lowering medication. At the follow-up examination, only 1.9% of
participants (n = 25) were LR, while 60.7% (n = 804) had 2 or more
RFs. About one-ﬁfth (n = 286) of participants had follow-up hs-CRPaseline risk factor status— the Chicago Healthy Aging Study.
P-valued
0 RFb 1 only RFc 2+ RFsc
423 449 193
) 32.8 (4.5) 33.1 (4.6) 32.8 (4.4) 0.040
2) 89 (21.0) 107 (23.8) 36 (18.7) b0.001
0.101
29 (6.9) 44 (9.8) 26 (13.5)
8) 385 (91.0) 395 (88.0) 162 (83.9)
9 (2.1) 10 (2.2) 5 (2.6)
) 15.2 (2.2) 14.6 (2.4) 14.5 (2.3) b0.001
–
9) 243 (57.5) 170 (37.9) 27 (14.0)
) 180 (42.6) 104 (23.2) 22 (11.4)
0 (0.0) 175 (39.0) 144 (74.6)
) 25.3 (2.5) 25.2 (3.4) 27.3 (4.0) –
0 (0.0) 34 (7.6) 49 (25.3) –
.1) 122.8 (8.5) 132.0 (15.5) 143.1 (14.1) –
) 73.5 (7.4) 77.6 (10.0) 83.5 (10.1) –
0 (0.0) 210 (46.8) 163 (84.5) –
0.3) 185.1 (27.9) 189.8 (35.2) 215.2 (44.7) –
0 (0.0) 27 (6.0) 66 (34.2) –
0 (0.0) 3 (0.7) 6 (3.1) –
b0.001
7 (1.7) 2 (0.5) 2 (1.0)
) 54 (12.8) 49 (10.9) 9 (4.7)
) 115 (27.2) 115 (25.6) 26 (13.5)
6) 247 (58.4) 283 (63.0) 156 (80.8)
) 133 (31.4) 163 (36.3) 80 (41.5) b0.001
) 116 (27.4) 128 (28.5) 48 (24.9) 0.696
1) 264 (62.4) 272 (60.6) 143 (74.1) b0.001
7) 234 (55.3) 236 (52.6) 116 (60.1) b0.001
) 83 (19.6) 107 (23.8) 45 (23.3) 0.363
) 124 (29.3) 165 (36.8) 74 (38.3) 0.041
1.9 (1.9) 2.2 (2.1) 2.1 (1.8) 0.111
ascular disease; DBP, diastolic blood pressure; FURF, follow-up risk factor; LR, low risk; RF,
tion, serum cholesterol b200mg/dL and no lipid-loweringmedication, not smoking, BMI b
/m2, no diabetes.
40 mg/dL or using lipid-lowering medication, smoking, BMI ≥30.0 kg/m2, diabetes
nents.
Table 2
Adjusted odds ratios (95% CI) for hs-CRP ≥ 3 mg/L at follow-up (2007–10) by baseline
(1967–73) risk factor status and single baseline risk factors — the Chicago Healthy Aging
Study.
N OR (95% CI)
Model 1a Model 2a
Baseline RF statusb
LR 259 1.00 1.00
0 RF 423 1.25 (0.83–1.87) 1.35 (0.89–2.03)
1 only RF 449 1.56 (1.05–2.31) 1.61 (1.08–2.40)
≥2 RFs 193 1.55 (0.96–2.50) 1.69 (1.04–2.75)
β coefﬁcient/P trendc 0.16 (0.023) 0.18 (0.014)
Single baseline risk factors
Smoking status
Never smoker (ref.) 608 1.00 1.00
Former smoker 397 1.14 (0.82–1.59) 1.14 (0.82–1.59)
Current smoker 319 1.75 (1.26–2.43) 1.69 (1.21–2.36)
SBP/DBP, mm Hg 612 1.00 1.00
≤120/≤80, no med. (ref.) 339 1.17 (0.84–1.63) 1.21 (0.87–1.70)
121–139, no med. ≥140/90
or on med.
373 0.73 (0.51–1.05) 0.75 (0.52–1.08)
Serum total chol., mg/dL
b200, no med. (ref.) 892 1.00 1.00
200–239, no med. 339 0.81 (0.59–1.13) 0.90 (0.64–1.27)
≥240 or on med. 93 1.27 (0.76–2.12) 1.46 (0.85–2.49)
BMI (kg/m2)
b25 (ref.) 685 1.00 1.00
25–29 556 1.29 (0.95–1.75) 1.33 (0.97–1.82)
≥30.0 83 2.03 (1.18–3.49) 2.00 (1.16–3.46)
Diabetes 9 0.34 (0.04–2.86) 0.35 (0.04–2.93)
Abbreviations: see Table 1 footnotes.
The bold-faced indicates OR (95%CI) signiﬁcance level of b 0.05. The Italic and bold-faced
indicate the signiﬁcant results for the trend test across4 baseline RF groups.
a Model 1: Adjusted for baseline age, sex, and race; Model 2: Adjusted for variables in
Model 1 plus education attainment, and current cancer, taking aspirin, taking lipid-lower-
ing medication, and presence of ECG major abnormalities/CVD.
b Deﬁnition of baseline RF status: see Table 1 footnotes.
c P value for trend across 4 baseline RF groups.
Table 3
Adjusteda odds ratios (95% CI) for Hs-CRP ≥3 mg/L follow-up (2007–10) by baseline
(1967–73) and follow-up risk factor status — the Chicago Healthy Aging Study.
Baseline RF statusb Men Women
N ORs (95% CI) N ORs (95% CI)
LR 129 1.00 130 1.00
RF 334 1.65 (0.90–3.01) 89 1.07 (0.57–2.00)
Only 1 RF 342 1.93 (1.07–3.50) 107 1.47 (0.81–2.64)
≥2 RFs 157 1.90 (0.97–3.73) 36 1.91 (0.84–4.33)
β coefﬁcient/P trendc 0.18/0.057 0.21/0.078
Abbreviations: CI indicates conﬁdence interval and see Table 1 footnotes.
The bold-faced indicates OR (95%CI) signiﬁcance level of b 0.05
a Adjusted for baseline age, race, education attainment, and current cancer, taking
aspirin, lipid-lowering medication, and presence of ECG major abnormalities/CVD.
b Deﬁnition of baseline RF status: see Table 1 footnotes.
c P value for trend across 4 baseline RF groups.
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≥2 mg/L (Table 1).
The age-sex-race adjusted prevalence of hs-CRP ≥ 3 mg/L at follow-
upwas lowest among the baseline LR group and progressively increased
with higher RFs (17% vs. 20–24%), with P-value for trend across four RF
groups=0.023. Similar resultswere observed for hs-CRP ≥ 2mg/L, with
P-value for trend = 0.002 (results not tabulated).
Odds ratios (ORs) and 95% conﬁdence interval (CI) for hs-CRP
≥3 mg/L at the follow-up examination by overall baseline RF status
and by single RF at baseline with adjustment for baseline age, sex, and
race (Model 1), and with further adjustment for education attainment,
current cancer, major ECG abnormality/CVD status, and aspirin and
lipid-lowering medication use (Model 2) (Table 2). Similar results
were observed in both models. Compared with the baseline LR group,
multivariate adjusted odds of elevated hs-CRP levels at follow-up in all
other RF groups were higher – ORs (95% CI) for elevated follow-up
CRP levels in baseline 0 RF, 1 RF, and 2+ RFs groups were 1.35 (0.89–
2.03), 1.61 (1.08–2.40), and 1.69 (1.04–2.75), respectively. When RF
statuswas used as a continuous variable to test for trends across RF stra-
ta, there was a graded, direct association across four categories of
baseline RF groups, with elevated hs-CRP at follow-up (β coefﬁcient/
P-trend = 0.18/0.014). Similar results were observed with the cut-
point of hs-CRP ≥2 mg/L (β coefﬁcient/P-trend = 0.21/0.002) (results
not shown).
In the analyses testing the linear association across 4 baseline RF
groups and natural log-transformed follow-up hs-CRP, adjusted geo-
metric mean of hs-CRP was also lowest in LR group, and highest in the
2+ RFs group. There was also a direct association across baseline RF
groups, from LR to very high risk, with follow-up hs-CRP levels (β
coefﬁcient/P-trend = 0.07/0.009) (results not tabulated).
In analyses of the relationship between each baseline RF and hs-CRP
level, cigarette smoking status and BMI levels were associated with
follow-up hs-CRP levels. The odds of hs-CRP ≥3 mg/L were 1.7
times higher in those who were current smokers at baseline versus
those who had never smoked, and two-fold in those who were
obese compared to those who had normal weight at baseline. No as-
sociations of baseline hypertension, hypercholesterolemia, and dia-
betes with follow-up hs-CRP levels were found.
With inclusion of 39-year change in BMI level, the associations of both
baseline smoking and BMI levels with follow-up hs-CRP level remained
signiﬁcant. For example, β coefﬁcients/P-values for the association of
baseline BMI as a continuous variable and elevatedhs-CRPwith andwith-
out 39-year change in BMI level were 0.09/b0.0001 and 0.07/0.002, re-
spectively. Change in BMI also showed a strong association with hs-CRP
level at follow-up (P-value b 0.0001) (results not tabulated).
In secondary sex-speciﬁc analyses (Table 3), a similar trend was ob-
served in both men and women, consistent with the main analyses for
all participants. We also observed similar results in sensitivity analyses
of the sample excluding participants who reported having fever within
two weeks before the exam or were current HRT users, as well as of the
samplewithout the exclusion of participantswith hs-CRP N 10mg/L. For
example, in the latter sample, adjusted ORs (95% CI) for follow-up hs-
CRP ≥ 3 mg/L were: 1.39 (0.96–2.04), 1.50 (1.04–2.17), and 1.72
(1.10–2.69) in baseline 0 RF, 1 RF, and 2+ RFs groups, respectively,
compared with the baseline LR group, (results not tabulated).
Discussion
Mainﬁndings of this 39-year prospective population studywere that
both women and men with adverse CVD risk proﬁles in young
adulthood/early middle age had higher odds of elevated hs-CRP levels
in older age than those who were originally low risk. The association
remained with adjustment for multiple traits. There were also graded,
direct associations across baseline RF strata with elevated hs-CRP levels
at follow-up. The associations weremainly due to participants' baseline
smoking status and BMI, independent of 39-year change in BMI levels.The beneﬁts of having favorable levels of all major CVD RFs in young
adulthood and middle age on subsequent health outcomes at older age
have beenwell documented by our research teamand others. For exam-
ple, life expectancy for the low-risk group was estimated greater by
5.8 years for CHA women aged 40–59 years, and by 9.5 years for CHA
men aged 18–39 years compared with the not-LR groups (Stamler
et al., 1999). LR was also associated with lower CVD morbidity (Lloyd-
Jones et al., 2006), better health-related quality of life (Daviglus et al.,
2003; Strandberg et al., 2004), and lower heath care costs (Daviglus
et al., 2005). The concept of LR therefore, has been a focus on the new
strategic directions in the impact goals of the American Heart Associa-
tion for CVD health promotion and disease prevention, especially pri-
mordial prevention, through 2020 and beyond (Lloyd-Jones et al.,
2010). While there is an abundance of literature on the association of
LR on other outcomes, information on associations of LR proﬁles and
239T.-H.T. Vu et al. / Preventive Medicine Reports 2 (2015) 235–240markers of inﬂammation is limited, especially evidence frompopulation
studies with decades-long follow-up.
CRP is an acute phase reactant that is a marker for underlying sys-
temic inﬂammation. CRP has been found to be associated with future
CVD events and mortality (Buckley et al., 2009; Kengne et al., 2012;
Libby et al., 2002; Ridker, 2003; Ridker et al., 2000; Strandberg and
Tilvis, 2000). It has been suggested that inﬂammatory processes play a
role in both initiation and progression of atherosclerosis. CRP therefore
has been hypothesized to be an indicator of the presence and extent of
underlying subclinical atherosclerosis and amarker of the development
of new atherosclerotic lesions (Libby et al., 2002; Ross, 1999). Although
there has been debate on the role of CRP in predicting CVD/CHD events,
assessment of CRP levels is recommended as potentially useful by the
American College of Cardiology and the American Heart Association
2013 guidelines for evaluation of patients with risk assessment levels
indicating uncertainty in decision making (Goff et al., 2014). Thus,
data on long-term associations of CVD risk proﬁles and hs-CRP levels
may not only add evidence on the beneﬁts of LR, but may also suggest
possible underlying mechanisms of the long-term associations of CVD
risk proﬁles and CVD.
Previous studies on CVD RFs and CRP however, have focused only on
cross-sectional associations of single CVD risk factors, including obesity
or body mass index (BMI) (Arena et al., 2006; Ganguli et al., 2011; Ishii
et al., 2012; Khoo et al., 2011; Strandberg and Tilvis, 2000; Visser et al.,
1999), smoking (Khoo et al., 2011; Strandberg and Tilvis, 2000; Zhang
et al., 2008), blood pressure (Khoo et al., 2011; Lakoski et al., 2005),
serum cholesterol (Chiu et al., 2012; Ganguli et al., 2011), and diabetes
(Chiu et al., 2012). They also failed to address the impact of LR proﬁle on
CRP levels. To our knowledge, this study is the ﬁrst to examine the long-
term association of LR risk proﬁle in younger age to hs-CRP levels in
older age, based on a large population of both men and women.
Our ﬁndings are consistent with those from previous studies on the
long-term association of LR proﬁle and health outcomes later in life. For
instance, our earlier study on the CHA cohort suggested that with
31 years of follow-up, LR participantswere less likely to have subclinical
coronary atherosclerosis, as measured by coronary artery calcium than
non-LR participants (Daviglus et al., 2004). Also, in a recent publication
using data from CHAS, we found a 39-year association of LR status with
the risk of atherosclerosis in the extremities. The likelihood of having
low ankle brachial index/peripheral arterial disease 39 years later in
persons with LR at baseline was 86% lower than in those with 2+ RFs
at baseline (Vu et al., 2012).
Regarding the association of individual RFs with CRP, we found
that baseline smoking and high BMI were predictors of elevated hs-
CRP levels. Those ﬁndings are consistent with results from previous
short-term or cross-sectional studies (Khoo et al., 2011; Strandberg
and Tilvis, 2000; Visser et al., 1999). For instance, in the Third Na-
tional Health and Nutrition Examination Survey, men and women
who were obese or overweight were more likely to have an elevated
CRP level compared to those with normal-weight (Visser et al.,
1999), and the likelihood of high CRP levels was about 1.5 times
higher in current smokers than in non-current smokers (Khoo
et al., 2011). Our ﬁndings extend these results, showing that BMI
level at younger age was independently associated with CRP levels
at much older age, regardless of current BMI level.
The relationships of CRP to hypertension or hypercholesterolemia
have remained unclear, with inconsistent ﬁndings from previous
studies (Chiu et al., 2012; Chuang et al., 2013; Lakoski et al., 2005;
Strandberg and Tilvis, 2000). We did not ﬁnd any association be-
tween baseline hypertension or hypercholesterolemia and CRP
level at follow-up. As persons with hypertension or hypercholester-
olemia in younger ages who survived until older ages may have been
more likely to use medication therapy such as statin over time, this
may have modiﬁed those decade-long associations and may be a
part of the explanation for our ﬁndings. There was no association of
baseline diabetes and follow-up CRP, however there were only afew participants with baseline diabetes and those were likely type
1 diabetics, therefore, the association could not be evaluated in this
study.
Furthermore, previous studies have reported the effect of sex on the
association of LR status and CRP (Arena et al., 2006); our study revealed
a similar trend in both genders on the association of LR proﬁle and CRP.
This study has important strengths. First, the 39-year follow-up
allowed us to study for the ﬁrst time CVD risk factor status in young
adulthood/early middle age and its association with CRP levels in
older age, with men and women of varied socioeconomic and ethnic
background. Second, also for the ﬁrst time, we were able to assess
such long-term associations independently of changes in RF status.
Despite the strengths of this study, it also has several limitations.
First, CRPwasmeasured only at the 39-year follow-up,whichprevented
us from examining relations of single and multiple RFs to the progres-
sion of CRP level over time. Second, because of the long interval between
examinations, our study may have been affected by survival bias. How-
ever, this bias is common in most longitudinal studies with decades-
long follow up. We would anticipate that individuals with higher RF
burdens at younger agewould have beenmore likely to die in the inter-
im, and that these individuals would also have beenmore likely to have
high CRP levels than those whowere LR. In addition, although informa-
tion on current BP and lipid-loweringmedication use was available and
was used for adjustment in the analyses, intake over time may have
modiﬁed CRP levels; we are unable to address this issue in this study.
Nevertheless, if anything, we may have underestimated the strength
of the long-term association of CVD RF proﬁles with hs-CRP.
In conclusion, our study provides new evidence on the associa-
tion of CVD RF proﬁles earlier in adult life and hs-CRP levels much
later in life. Favorable levels of all CVD RFs in younger ages, especially
not smoking and BMI b25 kg/m2 are associated with lower hs-CRP
levels in older age. Our data indicate the importance of LR proﬁle
and healthy lifestyles favorably inﬂuencing RFs in early adulthood
(Liu et al., 2012), as they are associated with lower risk of systemic
inﬂammation, which may play a role in the pathogenesis of coronary
atherosclerosis (Libby et al., 2002; Ross, 1999). They also underscore
the importance of increasing the prevalence of low-risk status and
healthy lifestyles among Americans as a means of achieving long-
term cardiovascular health, consistent with the recommendations
of the American Heart Association 2020 Impact Goals (Lloyd-Jones
et al., 2010). As such, the study supports public health initiatives
aimed at increasing prevalence of low-risk persons and healthy life-
styles to prevent or delay onset of CVD.
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